WUXAY
WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | 1.59 | $12.4B | $2.4B |
| 2025 Q4 | 2.49 | $12.6B | $3.8B |
| 2025 Q3 | 1.21 | $12.0B | $9.9B |
| 2025 Q2 | 1.72 | $11.1B | $2.9B |
| 2025 Q1 | 1.29 | $9.7B | $2.5B |
| 2024 Q4 | 1.01 | $11.5B | $2.5B |
| 2024 Q3 | 0.79 | $10.5B | -$981M |
| 2024 Q2 | 0.79 | $9.2B |
| $2.0B |